Beta Blockers for Peripheral Arterial Disease

Beta-blockers and peripheral arterial disease

Beta-blockers and health-related quality of life in patients with peripheral arterial disease and COPD

BACKGROUND Beta-blockers are frequently withheld in patients with cardiovascular disease who also have chronic obstructive pulmonary disease (COPD) because of concerns that they might provoke bronchospasm and cause deterioration in health status. Although beta1-selective beta-blockers are associated with reduced mortality in COPD patients, their effects on health status are unknown. The aim of ...

Prevalence of Peripheral Arterial Disease in Diabetic Patients

Objective: Peripheral Arterial Disease (PAD) is a state characterized by atherosclerotic occlusive disease of lower extremities. Diabetes is the main risk factor for PAD. Material and Methods: To assess the prevalence of PAD, a cross sectional study was performed on 352 diabetic patients who referred to Yazd diabetes research center from 2007 to 2010. Vascular assessment was done by measuring ...

Surgical infrainguinal revascularization for peripheral arterial disease: factors affecting patency rate

Background: Peripheral arterial disease is a source of morbidity and mortality. Surgical vascular reconstruction is a treatment option but probability of failure and complications are important concerns. In this study, we evaluated outcome of surgical infrainguinal reconstruction and factors affecting graft patency for a period of one year. Methods: In this cohort study, 85 consecutive patie...

Beta-blockers for coronary heart disease in chronic kidney disease.

BACKGROUND Limited data exist on whether the cardioprotective benefit of beta-blockers is modified by the presence of chronic kidney disease (CKD). METHODS A post hoc analysis of the data from the Bezafibrate Infarction Prevention (BIP) study was performed. CKD was defined according to the Modification of Diet in Renal Disease (MDRD) equation as an estimated glomerular filtration rate (GFR) <...